Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ilan Hadar
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- -0.25
- Country
- IL
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -31.26
Financials
Net Income
$-3.55MEBITDA
$-3.68MFree Cash Flow
$-2.92MEPS (diluted)
$-5.17Shares Outstanding (diluted)
687.4K+6147.0%Operating Expenses
$3.68MCash & Debt
$2.23MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-11.91M | $-89.60 |
| 2024 | $0.00 | $-16.44M | $-3953.62 |
| 2023 | $0.00 | $-4.94M | $-6634.98 |
| 2022 | $0.00 | $-3.21M | $52.37 |
| 2021 | $0.00 | $-755.2K | $-68.63 |
| 2020 | $0.00 | $-195.9K | $-17.79 |
Valuation
SLXNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+0.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·7d ago·Negative
Silexion Therapeutics Announces Exercise of Warrants Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company's ordinary shares originally issu…
View source ↗ - Newsglobenewswire.com·27d ago·Negative
…Participate in September 2026 Industry and Investor Conferences Grand Cayman, Cayman Islands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that members of its management team will participate in the following industry and investor conferences in September 2026: Oncology & Immunology Innovation Partnering & Lic…
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026 following clinical trial authorizations from regulators in both Israel and Germany
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,846,161 of the Company's ordinary shares (or ordinary share equivalents) and series E warrants to
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-9.10 per share
Typical surprise +15.3% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-5.17 vs $-21.20beat
- Tue, May 12$-8.50 vs $-12.90beat
- Tue, Mar 17$-23.85 vs $-1.17miss
- Wed, Nov 12$-28.80 vs $-34.00beat
- Tue, Aug 12$-43.20 vs $-31.50miss
- Tue, May 13$-38.98 vs $-33.00miss
Estimates and results for SLXN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SLXN officers and directors.
- Bought
- —
- Sold
- $31k
0 trades
1 trade
- Shirvan Mitchellsold
49 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SLXN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.